Galectin Therapeutics (NASDAQ:GALT) Insider Sells $136,871.68 in Stock

19 Dec 2025, 18:10 by Amy Steele · The Cerbat Gem

Galectin Therapeutics Inc. (NASDAQ:GALT – Get Free Report) insider Khurram Jamil sold 19,442 shares of the firm’s stock in a transaction dated Wednesday, December 17th. The stock was sold at an average price of $7.04, for a total value of $136,871.68. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Khurram Jamil also recently made the following trade(s):

On Thursday, November 13th, Khurram Jamil sold 121,117 shares of Galectin Therapeutics stock. The shares were sold at an average price of $5.47, for a total value of $662,509.99.

Galectin Therapeutics Trading Down 28.9%

Shares of Galectin Therapeutics stock traded down $1.78 on Friday, reaching $4.38. The stock had a trading volume of 4,104,617 shares, compared to its average volume of 417,051. The business’s 50 day moving average is $5.57 and its two-hundred day moving average is $4.15. Galectin Therapeutics Inc. has a 1 year low of $0.73 and a 1 year high of $7.13. The company has a market cap of $282.38 million, a P/E ratio of -7.42 and a beta of 0.95.

Galectin Therapeutics (NASDAQ:GALT – Get Free Report) last posted its earnings results on Friday, November 14th. The company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.02). On average, equities analysts anticipate that Galectin Therapeutics Inc. will post -0.73 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on the company. HC Wainwright lifted their price objective on Galectin Therapeutics from $6.00 to $11.00 and gave the company a “buy” rating in a research note on Wednesday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Galectin Therapeutics in a report on Wednesday, October 8th. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Galectin Therapeutics presently has an average rating of “Hold” and an average price target of $11.00.

View Our Latest Stock Analysis on Galectin Therapeutics

More Galectin Therapeutics News

Here are the key news stories impacting Galectin Therapeutics this week:

Positive Sentiment: FDA written response aligns with the company on the proposed patient population for a registration trial of belapectin and the company will pursue a follow‑up Type C meeting to finalize trial design; management says new biomarker data will be presented. This reduces some regulatory uncertainty for the lead program. Galectin Therapeutics Provides Regulatory Update
Positive Sentiment: Galectin secured a $10M unsecured, convertible line of credit from its chairman and extended maturities on related notes, which management says funds operations into at least March 2027 — a near‑term liquidity buffer while belapectin development continues. Regulatory update & financing
Neutral Sentiment: Technically, the stock recently crossed above its 200‑day moving average — a bullish technical sign for some traders, but not a fundamental change. Shares Cross Above 200-Day Moving Average
Negative Sentiment: Significant insider selling: multiple insiders (CEO Joel Lewis, Director Harold H. Shlevin, CMO Khurram Jamil) sold large blocks of stock on Dec. 16–17 at prices in the $6.66–$7.06 range — and a major shareholder (Fund L.P. 10X) also sold ~30,681 shares. The concentrated selling likely pressured the share price despite the regulatory/financing news. Insider Selling: Galectin Therapeutics
Negative Sentiment: While HC Wainwright maintained a Buy and raised its price target to $11 (from $6), analyst optimism can be slower to offset immediate selling pressure from insiders and short‑term traders. HC Wainwright maintains Buy, raises target

Hedge Funds Weigh In On Galectin Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Bank of America Corp DE boosted its stake in shares of Galectin Therapeutics by 101.4% during the fourth quarter. Bank of America Corp DE now owns 38,358 shares of the company’s stock valued at $49,000 after purchasing an additional 19,316 shares during the period. Nuveen LLC bought a new stake in Galectin Therapeutics in the 1st quarter worth $34,000. HighTower Advisors LLC grew its holdings in Galectin Therapeutics by 244.1% in the 1st quarter. HighTower Advisors LLC now owns 77,375 shares of the company’s stock worth $94,000 after acquiring an additional 54,889 shares during the last quarter. Geneos Wealth Management Inc. increased its position in shares of Galectin Therapeutics by 8.8% in the first quarter. Geneos Wealth Management Inc. now owns 423,235 shares of the company’s stock valued at $516,000 after acquiring an additional 34,300 shares during the period. Finally, Retirement Guys Formula LLC raised its stake in shares of Galectin Therapeutics by 2.7% during the second quarter. Retirement Guys Formula LLC now owns 159,593 shares of the company’s stock valued at $337,000 after acquiring an additional 4,250 shares during the last quarter. 11.68% of the stock is currently owned by hedge funds and other institutional investors.

Galectin Therapeutics Company Profile

(Get Free Report)

Galectin Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel therapies that target galectin proteins, which are implicated in fibrotic, inflammatory and malignant diseases. The company’s lead product candidate, belapectin (formerly GR-MD-02), is a galectin-3 inhibitor being evaluated in Phase 2 clinical trials for nonalcoholic steatohepatitis (NASH) with cirrhosis. In addition to its core pipeline in fibrotic liver disease, Galectin Therapeutics continues to explore the potential of its galectin inhibitors in oncology and other indications driven by abnormal tissue remodeling.